India sees a significant rise in overweight and obese populations recently. Rural areas show a particularly sharp increase in these health ...

A parliamentary committee proposes mandatory kidney function tests for adults aged twenty and above. High-risk individuals will undergo ann...

Diabetes: Recent studies reveal that metformin may influence blood sugar management via the brain. This medication stimulates a distinct br...

Demand for nutrition professionals is rapidly rising across India. Hospitals and digital health platforms are hiring more dietitians and ed...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

Pfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...

Tirzepatide and semaglutide dominate India's anti-obesity drug market, holding a 75% share. While seen as vital tools by doctors, experts c...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening it...

Novo Nordisk has introduced its weight-loss drug, Wegovy, in India. This launch follows Eli Lilly's entry into the market. The company aims...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle di...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Ryb...

India plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a govern...

India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...

According to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...

Belgium life science company, Kitozyme entered into in-licensing agreement with Corona Remedies for fat binder anti-obesity drug.

The government has banned manufacturing and sale of anti-obesity medicine Sibutramine and its combination drugs sold under various brands d...

Your fat loss is revenue gain for pharma companies. As obesity is fast becoming major concern in developing countries, sales of lifestyle r...